{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000142","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.798409+00:00","generated_at":"2026-05-31T12:12:00.585415+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance","bullets":["Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.","Bioservices services revenue $64.5M (+144% YoY) including $50M Janssen arbitration settlement; cost $211.6M with asset write-down.","Updated FY2024: total revenue $1,050-$1,125M (raised); net loss $(314)-$(274)M (wider); adj. EBITDA $140-$180M (raised).","Asset sales: $30M Baltimore-Camden site sale expected Q3 2024; $75M from RSDL sale to SERB; $50M Janssen dispute resolution.","Impairment $27.2M in Q2 vs $306.7M a year ago, related to Bayview and Rockville asset groups."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000142","json":"https://secwatch.observer/filing/0001367644-24-000142.json","markdown":"https://secwatch.observer/filing/0001367644-24-000142.md","text":"https://secwatch.observer/filing/0001367644-24-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/0001367644-24-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/ebs-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:12:00.585415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}